仁和药业公告，自2025年11月14日披露控股股东仁和集团拟减持不超300万股、占总股本0.2143%计划 后，截至本公告披露日，仁和集团实际未减持股份，持股仍为3.25亿股，占23.2367%，现决定提前终止 该减持计划。 ...

Core Viewpoint - The traditional Chinese medicine sector experienced a decline of 0.9% on December 29, with *ST Changyao leading the drop. The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1]. Group 1: Stock Performance - The following stocks in the traditional Chinese medicine sector showed notable performance: - WoHua Pharmaceutical (002107) closed at 6.33, up 2.43% with a trading volume of 106,100 shares and a transaction value of 65.58 million yuan [1]. - Tianmu Pharmaceutical (600671) closed at 17.39, up 1.81% with a trading volume of 22,600 shares and a transaction value of 39.17 million yuan [1]. - Weikang Pharmaceutical (300878) closed at 25.75, up 0.66% with a trading volume of 20,500 shares and a transaction value of 53.04 million yuan [1]. - Tongrentang (600085) closed at 32.46, up 0.65% with a trading volume of 168,300 shares and a transaction value of 221 million yuan [1]. - Yunnan Baiyao (000538) closed at 56.69, down 0.02% with a trading volume of 61,100 shares and a transaction value of 346 million yuan [1]. Group 2: Capital Flow - The traditional Chinese medicine sector saw a net outflow of 689 million yuan from institutional investors, while retail investors contributed a net inflow of 462 million yuan [2]. - Notable capital flows for specific stocks include: - Tongrentang (600085) had a net inflow of 28.03 million yuan from institutional investors, but a net outflow of 19.15 million yuan from retail investors [3]. - Wanbangde (002082) experienced a net inflow of 12.49 million yuan from institutional investors, with a net outflow of 9.44 million yuan from retail investors [3]. - Ma Yinglong (600993) had a net inflow of 5.11 million yuan from institutional investors, while retail investors saw a net inflow of 3.19 million yuan [3].

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2025-12-29 | 000623 | 吉林敖东 | 18.68 | 18.90 | | 353.05 招商证券股份有限 | 中山证券有限责任 | | | | | | | | 公司天津友谊北路 | 公司湖北分公司 | | | | | | | | 证券营业部 | | 12月29日，吉林敖东大宗交易成交18.9万股，成交额353.05万元，占当日总成交额的1.81%，成交价 18.68元，较市场收盘价19.62元折价4.79%。 ...

Group 1: Report Industry Investment Rating - No relevant content provided Group 2: Core Views of the Report - The market's continuous rise last week was due to the phased repair of risk appetite driven by cyclical sectors. The main driving force of the market came from internal structural changes, with cyclical sectors led by non - ferrous metals driving the index up. The repair of risk appetite was also supported by the external environment such as the phased appreciation of the RMB exchange rate and the marginal improvement of overseas liquidity expectations [5]. - The Spring Festival - before market still has upward space, and there are short - term opportunities for bottom - fishing. The main risk factors restricting the market have weakened, and risk appetite is expected to remain high. The market is in a stage of preparing for the Spring Festival - before market, and the short - term market is likely to rise gradually with internal structural adjustments [8]. - The technology theme is the most elastic main line in the Spring Festival market, focusing on sub - sectors such as robotics, commercial aerospace, and nuclear power. Overseas computing power and semiconductor - related sectors can be configured with a medium - term holding strategy. The non - banking financial sector has certain allocation value. In the consumer sector, it is more appropriate to grasp thematic trading opportunities, focusing on sports consumption, medical devices, and traditional Chinese medicine [7]. Group 3: Summary by Directory Market Review - **Market Performance**: Most major market indices rose last week, with the ChiNext 50 having the largest increase of 4.07%. Among the major industry indices, the Materials Index and the Information Technology Index performed relatively well, with weekly increases of 5.85% and 4.36% respectively, while the Daily Consumption Index and the Telecommunication Services Index performed weakly, with decreases of - 0.65% and - 0.34% respectively. Among the 30 Shenwan primary industries, 23 industries rose, with non - ferrous metals, national defense and military industry, and power equipment having larger increases of 6.43%, 6.00%, and 5.37% respectively, and beauty care, social services, and banks having larger decreases of - 1.08%, - 1.05%, and - 1.01% respectively [9][14][17]. - **Trading Heat**: The average daily trading volume of the Wind All - A Index last week was 1,965.166 billion yuan (the previous value was 1,760.484 billion yuan), at a relatively high historical level (87.50% of the three - year historical quantile) [19]. - **Valuation Tracking**: As of December 26, 2025, the valuation (PE_TTM) of the Wind All - A Index was 22.27, an increase of 0.48 from the previous week, at the 94.00% quantile of the past five - year history. Among the 30 Shenwan primary industries, 23 industries' valuations (PE_TTM) were repaired [24]. Market Observation - **Reasons for the Market Rise**: The continuous rise of the market last week was mainly due to the phased repair of risk appetite driven by cyclical sectors. There were no new direct positive factors from policies and news, and the driving force came from internal structural changes. The rise of the index was led by cyclical sectors such as non - ferrous metals, and the external environment also supported the repair of risk appetite [5]. - **Investment Recommendations**: Focus on the technology theme, overseas computing power and semiconductor - related sectors, the non - banking financial sector, and thematic trading opportunities in the consumer sector, especially sports consumption, medical devices, and traditional Chinese medicine [7]. Economic Calendar - The report mentions to pay attention to global economic data, but specific data details are not provided [26].

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Insights - The domestic innovative drug research and development is experiencing a recovery, with a focus on investment opportunities in the non-clinical safety evaluation sector [4][16] - The non-clinical safety evaluation industry is characterized by high competitive barriers and is expected to see increased demand due to the growth of domestic innovative drug development [5][20] - The pricing of experimental monkeys, crucial for safety evaluations, is expected to rise due to limited supply and increasing demand from innovative drug research [20] Summary by Sections Industry Overview - The closing index for the industry is 8254.26, with a 52-week high of 9323.49 and a low of 6764.34 [2] Recent Market Performance - In the week from December 22 to December 26, 2025, the A-share pharmaceutical and biotechnology sector fell by 0.18%, underperforming the CSI 300 index by 2.13 percentage points [6][22] - The raw material drug sector ranked first in performance among sub-sectors, increasing by 2.05%, while the hospital sector declined by 2.82% [6][22] Industry Perspectives 1. **Innovative Drugs and Industry Chain**: The innovative drug sector is in a continuous correction phase, driven by a retreat from previously optimistic expectations. However, clinical data from recent conferences supports the maturity of domestic innovative drugs [7][24] 2. **Investment Opportunities**: Companies with high certainty and less volatility in business development (BD) expectations are recommended, including Innovent Biologics and 3SBio [9][25] 3. **Medical Devices**: The medical device sector is expected to attract more investment as the pressure from centralized procurement diminishes, with leading companies showing improved performance [10][28] Recommendations - Focus on companies like Zhaoyan New Drug and Yino Science in the non-clinical safety evaluation sector, and consider investment in WuXi AppTec and Tigermed in the CRO and life science services sectors [20][26] - In the medical device sector, companies such as Mindray and Kangli Medical are highlighted for their potential recovery and growth [30][28]

Summary of Conference Call on Traditional Chinese Medicine Industry Industry Overview - The conference call focuses on the Traditional Chinese Medicine (TCM) industry, specifically the pricing of medicinal materials and the over-the-counter (OTC) market dynamics [1][3]. Key Points and Arguments - **Price Decline of Medicinal Materials**: The price of natural cow bile has decreased from over 1.4 million yuan per kilogram to 1.1 million yuan, indicating weak demand impacting upstream production companies [1][3]. - **Performance of OTC Products**: Data from nearly 100,000 small and medium-sized chain pharmacies, representing 20% market share, shows that products related to cold relief, such as Lianhua Qingwen capsules and pediatric Chiqiao Qingre granules, performed well in November, expected to drive growth in Q4 and Q1 of the following year [1][3]. - **Stability in Orthopedic and Digestive Products**: Sales of orthopedic and digestive products, such as Lingzhi Pharmaceutical's hemorrhoid ointment and Yunnan Baiyao's plaster preparations, remain stable. Yunnan Baiyao's Qixue Kang has maintained high double-digit growth since Q4 2024 due to academic promotion in grassroots medical institutions and chain pharmacies [1][3]. - **Pressure on Qi and Blood Supplement Products**: Products like Mayinglong hemorrhoid ointment and some from Jianmin Group face growth pressure, but this is expected to ease by December this year and into next year [1][3]. - **Healthy Inventory and Cash Flow Management**: Companies with excellent inventory management and stable cash flow, such as Mayinglong and Jiangzhong, have maintained positive growth since January, with no historical burdens [1][3][4]. - **Long-term Price and Demand Relationship**: There is a close relationship between medicinal material prices and demand. The decline in prices since Q3 of last year reflects weakened demand in Q1 and Q2, which has begun to impact the upstream raw materials market [1][5]. Additional Important Insights - **Focus on Stable Companies**: Investors are advised to pay attention to companies with stable operations, good cash flow, and effective inventory control, as well as the stabilization of medicinal material prices and the recovery of the OTC market [2][4]. - **Monitoring Market Dynamics**: Continuous monitoring of medicinal material price stabilization and monthly OTC data recovery is crucial for assessing the overall recovery of the OTC market [5].

Core Viewpoint - The recent market rally is primarily driven by a phase of risk appetite recovery led by cyclical sectors, with a lack of new positive external factors impacting the market [1][3]. Market Performance - Major indices such as the Wind All A, CSI 300, and CSI 2000 rose by 2.78%, 1.95%, and 3.06% respectively this week [2]. - The average daily trading volume for Wind All A increased from 1.76 trillion yuan to 1.97 trillion yuan, surpassing 2 trillion yuan on Friday [2]. - Approximately 52.20% of stocks in Wind All A saw price increases this week, indicating a confirmation of the upward trend in indices, albeit with a change in the manner of the rise [2]. Sector Analysis - The upward movement in indices was primarily driven by cyclical sectors, particularly non-ferrous metals, as industrial metal commodity prices strengthened significantly [3]. - The recovery in risk appetite is evident, supported by a temporary appreciation of the RMB and improved expectations for overseas capital inflow into the A-share market [3]. Future Outlook - The market is expected to maintain upward potential before the Spring Festival, with opportunities for low-level positioning in the short term [4]. - Current risk factors have weakened compared to previous periods, and high levels of risk appetite are likely to persist [4]. - The market is characterized by a phase of preparation for the pre-Spring Festival rally rather than a formal initiation of a major upward trend, with a focus on low-level positioning and structural adjustments [4]. Investment Recommendations - Focus on technology themes, particularly in robotics, commercial aerospace, and nuclear power sectors, as they are expected to be resilient during the spring market [5]. - Consider overseas computing and semiconductor-related sectors for medium-term investment strategies [5]. - Non-bank financial sectors hold certain allocation value at this stage [5]. - In the consumer sector, it is advisable to seize thematic trading opportunities, especially in areas related to service consumption and aging, such as sports consumption and medical devices [5].

Core Viewpoint - Fangsheng Pharmaceutical (603998) is focusing on the development of innovative traditional Chinese medicine (TCM) products, with plans to enhance its product pipeline and achieve significant sales growth in the coming years [1] Company Announcements - The company held a product launch event for its new product, Yao Xue Qu Feng Zhi Tong Granules, on December 21, 2025, discussing its operational status, R&D progress, and market strategy [1] - Yao Xue Qu Feng Zhi Tong Granules has been included in the 2025 National Medical Insurance Directory, with plans to cover over 500 medical institutions by 2026 [2] - Fangsheng Pharmaceutical has successfully launched two innovative TCM products and aims to create a product matrix with annual sales of 300-500 million yuan [2] - The industrial hemp subsidiary has achieved large-scale production and overseas sales [2]

转自：北京日报客户端 会议指出，构建党委统一领导、全面覆盖、权威高效的"大监督"工作格局，是提升公司治理现代化水平 的重中之重。岳浩延在部署监督工作时强调，要全面整合各类监督资源，着力构建权责清晰、协同高效 的"三道防线"监督网络，解决监督协同不足、穿透力不强等深层次问题，并特别指出，纪检监察机构在 其中要切实发挥政治监督的引领作用，履行好"监督的再监督"职责，确保大监督体系权威高效。 邸淑兵在讲话中强调，全系统必须清醒认识当前强化内部监督的极端重要性和现实紧迫性。他指出，近 期暴露出的问题已直接触及"生产安全、产品质量、品牌维护、廉洁从业"四条红线，形势严峻、刻不容 缓。"大监督"体系必须深度嵌入业务流程，围绕构建风险雷达预警、问题诊断处置、合规价值创造、信 息协同指挥"四大系统"扎实推进，真正成为保障集团战略落地的最强屏障。为切实维护"同仁堂"品牌声 誉，严厉杜绝一切违规使用品牌行为，会议再部署在全系统范围开展针对贴牌业务、产品质量、商标字 号、委托加工、控股控权、电商业务、宣传推广等专项排查行动，要求限期彻底排查到位，由集团各职 能部室及各级纪检组织全程督办、严查实效。 同仁堂集团召开"大监督"工作会， ...

Group 1 - The core point of the announcement is that Taiji Group's shareholder, Chongqing Taiji Medicinal Plant Resources Development Co., Ltd., plans to absorb and merge its wholly-owned subsidiary, Chongqing Fuling Xilan Biotechnology Co., Ltd., with no impact on the company's control and operational independence [1][2] - The merger involves the transfer of shares: Xilan Biotechnology currently holds 11.8953 million unrestricted circulating shares, accounting for 2.157% of the total share capital of Taiji Group, which will be fully inherited by the resources company after the merger [1] - Post-merger, the resources company's shareholding in Taiji Group will increase from 367,300 shares to 12.2626 million shares, raising its ownership percentage from 0.067% to 2.224% [1] Group 2 - The merger does not involve any changes in equity increase or decrease, and the controlling shareholder, Taiji Group Co., Ltd., along with its concerted parties, will maintain a total shareholding of 1.661 billion shares, representing 30.118% [1] - The announcement clarifies that the transaction will not affect the personnel, assets, finances, business, or institutional independence of Taiji Group, and there are no circumstances that would harm the interests of the company and all shareholders [1] - Both the resources company and Xilan Biotechnology are wholly-owned subsidiaries within the Taiji Group system, with the former focusing on traditional Chinese medicine cultivation and research, while the latter is dedicated to the development and research of biopharmaceutical products [2]